STTK
Shattuck Labs Inc.
$3.10
-$0.13(-4.02%)
68
Overall
60
Value
100
Tech
44
Quality
Market Cap
$198.70M
Volume
159.59K
52W Range
$0.69 - $3.38
Target Price
$3.75
Company Overview
| Mkt Cap | $198.70M | Price | $3.10 |
| Volume | 159.59K | Change | -4.02% |
| P/E Ratio | -2.6 | Open | $3.22 |
| Revenue | $5.7M | Prev Close | $3.23 |
| Net Income | $-75.4M | 52W Range | $0.69 - $3.38 |
| Div Yield | N/A | Target | $3.75 |
| Overall | 68 | Value | 60 |
| Quality | 44 | Technical | 100 |
No chart data available
About Shattuck Labs Inc.
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STTK | $3.10 | -4.0% | 159.59K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |